Japanese | English

| Sitemap |

Investor Relations  |  Environmental and Social Report  |  about Eisai  |  Inquiry

Eisai Global Site Investor Relations Environmental and Social Report about Eisai Potential Suppliers Inquiry

Understanding Eisai Company Introduction Video Annual Report 2010 Environmental and Social Report 2009			News Release List September 2, 2010 EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE August 30, 2010 EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE August 30, 2010 Abbott Japan and Eisai Submit Application for Additional Indication of Humira®, a Fully Human Anti-TNF Monoclonal Antibody, for the Treatment of Juvenile Idiopathic Arthritis in Japan
			What's New List September 2, 2010 Commitment & Passion for hhc “Spending Time With Patients is Key to human health care ~‘hhc Initiative 2010’” August 2, 2010 IR “First Quarter Financial Results Explanation for the Fiscal Year Ending March 31, 2011 [Material, Webcast]” July 30, 2010 IR “First Quarter Financial Results for the Fiscal Year Ending March 31, 2011”
			Information Corporate Governance Report updated (July 30, 2010) Notice of shareholder voting results for the 98th ordinary general meeting of shareholders (June 21, 2010) Notice of resolutions of the 98th ordinary general meeting of shareholders (June 18, 2010)

Privacy Policy  |  Terms of Use  |  Accessibility